Henan Newland Pharmaceutical Co. Ltd. A (301277) - Net Assets
Based on the latest financial reports, Henan Newland Pharmaceutical Co. Ltd. A (301277) has net assets worth CN¥1.51 Billion CNY (≈ $220.69 Million USD) as of June 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (CN¥1.77 Billion ≈ $258.37 Million USD) and total liabilities (CN¥257.50 Million ≈ $37.68 Million USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check asset resilience ratio of Henan Newland Pharmaceutical Co. Ltd. A to evaluate the company's liquid asset resilience ratio.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | CN¥1.51 Billion |
| % of Total Assets | 85.42% |
| Annual Growth Rate | 48.96% |
| 5-Year Change | N/A |
| 10-Year Change | N/A |
| Growth Volatility | 95.82 |
Henan Newland Pharmaceutical Co. Ltd. A - Net Assets Trend (2020–2024)
This chart illustrates how Henan Newland Pharmaceutical Co. Ltd. A's net assets have evolved over time, based on quarterly financial data. Also explore Henan Newland Pharmaceutical Co. Ltd. A (301277) total assets for the complete picture of this company's asset base.
Annual Net Assets for Henan Newland Pharmaceutical Co. Ltd. A (2020–2024)
The table below shows the annual net assets of Henan Newland Pharmaceutical Co. Ltd. A from 2020 to 2024. For live valuation and market cap data, see Henan Newland Pharmaceutical Co. Ltd. A market capitalisation.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | CN¥1.54 Billion ≈ $225.80 Million |
+6.45% |
| 2023-12-31 | CN¥1.45 Billion ≈ $212.11 Million |
+6.64% |
| 2022-12-31 | CN¥1.36 Billion ≈ $198.89 Million |
+234.47% |
| 2021-12-31 | CN¥406.38 Million ≈ $59.47 Million |
+29.67% |
| 2020-12-31 | CN¥313.39 Million ≈ $45.86 Million |
-- |
Equity Component Analysis
This analysis shows how different components contribute to Henan Newland Pharmaceutical Co. Ltd. A's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 224.7% over the analyzed period, indicating profitable operations and earnings retention.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Retained Earnings | CN¥511.47 Million | 33.16% |
| Other Components | CN¥1.03 Billion | 66.84% |
| Total Equity | CN¥1.54 Billion | 100.00% |
Henan Newland Pharmaceutical Co. Ltd. A Competitors by Market Cap
The table below lists competitors of Henan Newland Pharmaceutical Co. Ltd. A ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Zhejiang Xinzhonggang Thermal Power Co Ltd
SHG:605162
|
$654.18 Million |
|
Sichuan Expressway Company Limited
F:EXF1
|
$654.20 Million |
|
Latent View Analytics Limited
NSE:LATENTVIEW
|
$654.23 Million |
|
Wuxi Jinyang New Materials Co. Ltd. A
SHE:301210
|
$654.26 Million |
|
Jiangxi Yuean Advanced Materials Co Ltd
SHG:688786
|
$653.37 Million |
|
Sinostar Cable Co. Ltd.
SHE:300933
|
$653.26 Million |
|
Shenzhen Jinxinnong Feed Co Ltd
SHE:002548
|
$653.20 Million |
|
Zhejiang Jasan Holding Group Co Ltd
SHG:603558
|
$652.81 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Henan Newland Pharmaceutical Co. Ltd. A's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 1,448,017,462 to 1,542,189,227, a change of 94,171,765 (6.5%).
- Net income of 173,629,225 contributed positively to equity growth.
- Dividend payments of 80,016,000 reduced retained earnings.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | CN¥173.63 Million | +11.26% |
| Dividends Paid | CN¥80.02 Million | -5.19% |
| Other Changes | CN¥558.54K | +0.04% |
| Total Change | CN¥- | 6.50% |
Book Value vs Market Value Analysis
This analysis compares Henan Newland Pharmaceutical Co. Ltd. A's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 2.90x
- The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
- The price-to-book ratio has decreased from 7.64x to 2.90x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2020-12-31 | CN¥1.49 | CN¥11.40 | x |
| 2021-12-31 | CN¥1.37 | CN¥11.40 | x |
| 2022-12-31 | CN¥3.46 | CN¥11.40 | x |
| 2023-12-31 | CN¥3.69 | CN¥11.40 | x |
| 2024-12-31 | CN¥3.93 | CN¥11.40 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Henan Newland Pharmaceutical Co. Ltd. A utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 11.26%
- The company shows good efficiency in utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 23.90%
- • Asset Turnover: 0.40x
- • Equity Multiplier: 1.18x
- Recent ROE (11.26%) is below the historical average (19.67%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2020 | 37.80% | 27.35% | 0.83x | 1.67x | CN¥87.12 Million |
| 2021 | 28.56% | 22.38% | 0.77x | 1.66x | CN¥74.73 Million |
| 2022 | 9.76% | 21.09% | 0.41x | 1.13x | CN¥-3.29 Million |
| 2023 | 10.98% | 24.40% | 0.40x | 1.11x | CN¥14.18 Million |
| 2024 | 11.26% | 23.90% | 0.40x | 1.18x | CN¥19.41 Million |
Industry Comparison
This section compares Henan Newland Pharmaceutical Co. Ltd. A's net assets metrics with peer companies in the Drug Manufacturers - Specialty & Generic industry.
Industry Context
- Industry: Drug Manufacturers - Specialty & Generic
- Average net assets among peers: $1,347,197,696
- Average return on equity (ROE) among peers: 4.46%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Henan Newland Pharmaceutical Co. Ltd. A (301277) | CN¥1.51 Billion | 37.80% | 0.17x | $654.06 Million |
| Shenzhen Neptunus Bioengineering Co Ltd (000078) | $2.84 Billion | -41.97% | 9.13x | $1.22 Billion |
| Anhui Fengyuan Pharmaceutical Co Ltd (000153) | $638.89 Million | 0.88% | 0.70x | $438.59 Million |
| Shan Dong Dong-E E-Jiao Co Ltd (000423) | $1.05 Billion | 10.46% | 0.19x | $5.18 Billion |
| Livzon Pharmaceutical Group Inc (000513) | $1.07 Billion | 3.83% | 0.46x | $2.81 Billion |
| Wedge Industrial Co Ltd (000534) | $1.29 Billion | 11.69% | 1.47x | $2.95 Billion |
| Yunnan Baiyao Group Co Ltd (000538) | $35.11 Million | 18.13% | 0.80x | $13.85 Billion |
| Hainan Haiyao Co Ltd (000566) | $5.08 Billion | 1.71% | 1.08x | $949.23 Million |
| Tus Pharmaceutical Group Co Ltd (000590) | $141.91 Million | 11.01% | 0.32x | $391.07 Million |
| Northeast Pharmaceutical Group Co Ltd (000597) | $994.58 Million | 2.01% | 2.11x | $1.03 Billion |
| Jilin Aodong Pharmaceutical Group Co Ltd (000623) | $332.48 Million | 26.89% | 0.68x | $3.30 Billion |
About Henan Newland Pharmaceutical Co. Ltd. A
Newland Pharmaceutical Co., Ltd. engages in the research and development, production, and sale of pharmaceutical intermediates and APIs in China. It provides pharmaceutical intermediates, including L-4-hydroxyphenylglycine methyl ester, L-hydroxyphenylglycine potassium salt, L-4-hydroxyphenylglycine, and p-Toluenesulfonic acid. The company also offers APIs, such as ropivacaine hydrochloride, naph… Read more